Key result
Percutaneous transluminal septal myocardial ablation yielded a 10-year survival rate of 67%, comparable to an age- and sex-matched background population (P=0.06).
Why the study?
Does percutaneous transluminal septal myocardial ablation improve long-term survival and symptoms in patients with hypertrophic obstructive cardiomyopathy?
Population
279 patients with hypertrophic obstructive cardiomyopathy, mean age 59±14 years, 69% having ≥1 comorbidity…
Comparison
Percutaneous transluminal septal myocardial… vs Age- and sex-matched background population
Design
Cohort
Follow-up
mean 2.9±2.6 years (survival up to 10 years)
Authors
Loading...
Supports septal ablation in obstructive HCM with matched-population survival; leaves open randomized confirmation of benefit.
Cohort (n=279)
Yes
Does percutaneous transluminal septal myocardial ablation improve long-term survival and symptoms in patients with hypertrophic obstructive cardiomyopathy?
p-value: p=0.06
Percutaneous transluminal septal myocardial ablation in patients with hypertrophic obstructive cardiomyopathy provides sustained hemodynamic and symptomatic improvements with long-term survival comparable to an age- and sex-matched background population.
Jensen et al. (2011) conducted a cohort in hypertrophic obstructive cardiomyopathy (n=279). percutaneous transluminal septal myocardial ablation (PTSMA) vs. age- and sex-matched background population was evaluated on 10-year survival rate (p=0.06). Percutaneous transluminal septal myocardial ablation yielded a 10-year survival rate of 67%, comparable to an age- and sex-matched background population (P=0.06).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: